Hyperparathyroidism in the context of MEN2A: from genetics to clinical management

[1]  R. Rizzoli,et al.  Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism , 2022, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  F. Borson‐Chazot,et al.  Diagnostic Performance of 18F-Choline Positron Emission Tomography/Contrast-Enhanced Computed Tomography in Adenoma Detection in Primary Hyperparathyroidism after Inconclusive Imaging: A Retrospective Study of 215 Patients , 2022, Cancers.

[3]  E. Hindié,et al.  The EANM practice guidelines for parathyroid imaging , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  L. Bastholt,et al.  Multiple endocrine neoplasia type 2 (MEN2). , 2021, Seminars in cancer biology.

[5]  K. Lorenz,et al.  100-Year evolution of precision medicine and surgery for multiple endocrine neoplasia type 2A , 2020, Endocrine.

[6]  T. Bruckner,et al.  Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon‐specific penetrance and changes in management during the last four decades , 2017, Clinical endocrinology.

[7]  B. Carnaille,et al.  Hereditary hyperparathyroidism—a consensus report of the European Society of Endocrine Surgeons (ESES) , 2015, Langenbeck's Archives of Surgery.

[8]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[9]  C. Marcocci,et al.  Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism , 2015, Journal of Endocrinological Investigation.

[10]  G. Valk,et al.  Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperative workup, operative strategy and follow-up , 2013, Orphanet Journal of Rare Diseases.

[11]  P. Vestergaard,et al.  Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. , 2013, The Journal of clinical endocrinology and metabolism.

[12]  S. Antonini,et al.  Primary hyperparathyroidism as the first clinical manifestation of multiple endocrine neoplasia type 2A in a 5-year-old child. , 2011, Thyroid : official journal of the American Thyroid Association.

[13]  Martin Fassnacht,et al.  Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10 , 2011, Human mutation.

[14]  C. Lamas,et al.  MEN-2A syndrome and pulmonary metastasis , 2002, Postgraduate medical journal.

[15]  John P. Bilezikian,et al.  CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 , 2001 .

[16]  D. Lowe,et al.  Metastatic parathyroid carcinoma in the MEN2A syndrome , 1997, Clinical endocrinology.

[17]  P. Roger,et al.  Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type IIa: Retrospective French Multicentric Study , 1996, World Journal of Surgery.

[18]  H. Dralle,et al.  Primary hyperparathyroidism in multiple endocrine neoplasia type 2A , 1995, Journal of internal medicine.

[19]  P. Goodfellow,et al.  Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Goodfellow,et al.  Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. , 1993, Human molecular genetics.

[21]  P. Wermer.  Genetic aspects of adenomatosis of endocrine glands. , 1954, The American journal of medicine.

[22]  R. Eastell,et al.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. , 2014, The Journal of clinical endocrinology and metabolism.